Literature DB >> 2560979

A potent antagonist of the strychnine insensitive glycine receptor has anticonvulsant properties.

M J Sheardown1, J Drejer, L H Jensen, C E Stidsen, T Honoré.   

Abstract

5.7-Dinitro-quinoxaline-2.3-dione (MNQX) displaced [3H]glycine binding to cortical membranes but had no effect n [3H]3-((+/-)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid ([3H]CPP) binding. MNQX potently antagonized N-methyl-D-aspartate (NMDA)-evoked release of [3H]GABA from cultured cortical neurones, NMDA evoked spreading depression and NMDA depolarizations in the rat neo-cortex. All of these responses were reversed by addition of glycine to the perfusion media. These results suggested that MNQX is an antagonist at the strychnine-insensitive glycine receptor associated with the NMDA receptor/ionophore complex. Furthermore the compound was found to antagonise audiogenic seizures in DBA-2 mice indicating the potential of glycine antagonists of this type in anticonvulsant therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2560979     DOI: 10.1016/0014-2999(89)90312-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Molecular electrostatic potentials in aromatic substituted 4-hydroxyquino-2-lones: glycine/NMDA receptor antagonists.

Authors:  Kaustubh A Joshi; Dinannath D Patil; Shridhar P Gejji
Journal:  J Mol Model       Date:  2008-12-09       Impact factor: 1.810

2.  The Anticonvulsant Effect of Hydroethanolic Leaf Extract of Calotropis procera (Ait) R. Br. (Apocynaceae).

Authors:  Ernest Obese; Robert Peter Biney; Isaac Tabiri Henneh; Emmanuel Awintiig Adakudugu; Daniel Anokwah; Lovia Serwaa Agyemang; Eric Woode; Elvis Ofori Ameyaw
Journal:  Neural Plast       Date:  2021-06-26       Impact factor: 3.599

Review 3.  Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy.

Authors:  Roberta Celli; Francesco Fornai
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.